Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 611-930-7
CAS number: 60045-26-3
Observational data demonstrating no increase in adverse pregnancy
outcomes are important as they may be the only data to be critically
The study suggests that benzoyl benzoate and permethrin are safe in the
second and third trimesters of pregnancy.
There were no statistically significant differences in pregnancy
outcomes between women who were treated with either BBL (n = 444)
compared with their matched controls (n = 1,776) or permethrin (n = 196)
treated women and their matched controls (n = 784). Overall, only 10.9%
(n = 66) of treatments were in the first trimester. Retreatment rates
were higher with BBL 16.4%, than permethrin 9.7%, P = 0.038. Scabies was
more common during cooler periods.
There was no evidence of adverse effects on pregnancy outcome due to
topical 25% BBL or 4% permethrin
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again